FATE Earnings Date: Nov 12, 2026 (Estimated) — Fate Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is FATE's next earnings date?
Fate Therapeutics, Inc. (FATE) is expected to report Q3 2026 earnings on Thursday, November 12, 2026 at 8:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.27 on revenue of $1.1M.
How did FATE do in its last earnings report?
In its most recent report on Aug 13, 2026 (Q2 2026), Fate Therapeutics, Inc. posted EPS of -$0.25 versus the -$0.25 estimate, a beat of 3.9%. Revenue was $2.1M against a $1.3M estimate. The stock's 1-day post-earnings move was -7.4%.
How much does FATE stock move after earnings?
FATE beat EPS estimates in 6 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 8.6% (up or down) in the day after earnings.
About Fate Therapeutics, Inc.
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating advanced, programmed cellular immunotherapies. These innovative treatments are designed to combat cancer and various immune disorders across the globe. A significant portion of its development pipeline concentrates on NK- and T-cell immuno-oncology programs. Key candidates include FT516, which targets acute myeloid leukemia (AML), B-cell lymphoma, and advanced solid tumors; FT596 for B-cell lymphoma and chronic lymphocytic leukemia; FT538, addressing AML and multiple myeloma; FT576, also focused on multiple myeloma; FT819, aimed at both hematologic malignancies and solid tumors; FT536, another program for solid tumors; and FT500, intended for advanced solid tumors. The company also actively engages in strategic collaborations to advance its research and development. It holds an agreement with Ono Pharmaceutical Co. Ltd. for the joint development and commercialization of two novel, "off-the-shelf" iPSC-derived CAR T-cell therapies. Furthermore, Fate Therapeutics maintains a research collaboration and licensing deal with Juno Therapeutics, Inc., focusing on identifying small molecule modulators that can enhance the therapeutic efficacy of genetically engineered T-cell immunotherapies. A separate collaboration and option agreement exists with Janssen Biotech, Inc. Established in 2007, Fate Therapeutics, Inc. is based in San Diego, California.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-13 | Q2 2026 | -0.25 | -0.25 | +3.85% | $2.1M | ✅ Beat | -7.35% | -2.57% | -15.07% |
| 2026-05-13 | Q1 2026 | -0.28 | -0.26 | +7.14% | $1.3M | ✅ Beat | -5.11% | -16.00% | -12.44% |
| 2026-02-26 | Q4 2025 | -0.27 | -0.27 | +0.00% | $1.4M | ➖ Inline | +5.41% | -2.03% | -16.89% |
| 2025-11-13 | Q3 2025 | -0.28 | -0.27 | +3.57% | $1.7M | ✅ Beat | -4.59% | +0.96% | +10.58% |
| 2025-08-12 | Q2 2025 | -0.35 | -0.29 | +17.14% | $1.9M | ✅ Beat | +20.69% | +21.76% | +8.94% |
| 2025-03-05 | Q4 2024 | -0.43 | -0.44 | -2.33% | $1.9M | ❌ Miss | +14.90% | +11.59% | -24.87% |
| 2024-11-12 | Q3 2024 | -0.42 | -0.40 | +4.76% | $3.1M | ✅ Beat | -8.82% | -8.40% | -19.12% |
| 2024-08-13 | Q2 2024 | -0.47 | -0.33 | +29.79% | $6.8M | ✅ Beat | -2.10% | +9.88% | +11.98% |
Showing last 8 quarters.